Pharmacology
Conference Coverage
Nonhormonal drug for menopause symptoms passes phase 3 test
The novel NK3 receptor–inhibitor fezolinetant controlled vasomotor symptoms of menopause over 52 weeks in the phase 3 SKYLIGHT 2 trial.
News
Synthetic opioid use up almost 800% nationwide
More than 100,000 people in the United States died of an unintended drug overdose in 2021, a record high.
Conference Coverage
Breast cancer deaths take a big dip because of new medicines
Research model suggests a 58% overall mortality decline in 2019 from metastatic breast cancer.
Conference Coverage
SGLT2 inhibitors cut AFib risk in real-word analysis
Observational data add to a growing link between SGLT2 inhibitor treatment and atrial fibrillation prevention in people with type 2 diabetes.
Conference Coverage
Promising treatment option for incurable lung cancer described as ‘significant’
Investigators suggest this combo should be standard therapy for NSCLC going forward.
News
Opioid use in the elderly a dementia risk factor?
Exposure to these drugs may be another modifiable risk factor for dementia.
Conference Coverage
Genetic testing for best antidepressant accurate, cost effective
Had psychiatrists who treated patients in the study known about their metabolizing profiles, it “might have contributed to switches in medication...
News
ADA updates on finerenone, SGLT2 inhibitors, and race-based eGFR
ADA has made an interim change to its latest Standards of Medical Care, an update based on trial evidence and consensus about finerenone, SGLT2...
Conference Coverage
Schizophrenia patients in long-term facilities benefit from lower-dose antipsychotics
With careful monitoring, some with severe schizophrenia show improved stabilization, social engagement after their long-acting antipsychotic doses...
Conference Coverage
Novel drug ‘promising’ for concomitant depression, insomnia
Patients with more severe insomnia at baseline had a greater improvement in depressive symptoms.